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In an effort to maximize outcomes, recent expert guidelines recommendmore-intensive vancomycin dosing schedules to main-
tain vancomycin troughs between 15 and 20mg/liter. The widespread use of these more-intensive regimens has been associated
with an increase in vancomycin-induced nephrotoxicity reports. The purpose of this systematic literature review is to determine
the nephrotoxicity potential of maintaining higher troughs in clinical practice. All studies pertaining to vancomycin-induced
nephrotoxicity between 1996 and April 2012 were identified from PubMed, Embase, Cochrane Controlled Trial Registry, and
Medline databases and analyzed according to Cochrane guidelines. Of the initial 240 studies identified, 38 were reviewed, and 15
studies met the inclusion criteria. Overall, higher troughs (>15 mg/liter) were associated with increased odds of nephrotoxicity
(odds ratio [OR], 2.67; 95% confidence interval [CI], 1.95 to 3.65) relative to lower troughs of<15 mg/liter. The relationship be-
tween a trough of>15 mg/liter and nephrotoxicity persisted when the analysis was restricted to studies that examined only ini-
tial trough concentrations (OR, 3.12; 95% CI, 1.81 to 5.37). The relationship between troughs of>15 mg/liter and nephrotoxicity
persisted after adjustment for covariates known to independently increase the risk of a nephrotoxicity event. An incremental
increase in nephrotoxicity was also observed with longer durations of vancomycin administration. Vancomycin-induced neph-
rotoxicity was reversible in the majority of cases, with short-term dialysis required only in 3% of nephrotoxic episodes. The col-
lective literature indicates that an exposure-nephrotoxicity relationship for vancomycin exists. The probability of a nephrotoxic
event increased as a function of the trough concentration and duration of therapy.
Since its discovery in the 1950s, vancomycin has been a mainstayof therapy for serious Staphylococcus aureus infections. Although
vancomycinwasa second-line therapyearly in its life cycle, it emerged
as afirst-line agent for infectionsdue tomethicillin-resistantS. aureus
(MRSA) in the 1970s (1). Over the next several decades, its usage
dramatically increased due to the explosion of MRSA in both the
community and health care settings (2–4). Despite the recent avail-
abilityof alternativeagents, vancomycin still remains the treatmentof
choice for seriousMRSA infections (5).
Despite its widespread use, there are growing concerns about
the future role of vancomycin, particularly among patients who
have invasiveMRSA infections with vancomycinMICs of1mg/
liter (6). Although host- and pathogen-related factors have been
implicated as a cause, suboptimal vancomycin dosing has been
suggested as an alternative explanation for the poorer outcomes
among these patients. To counteract some of these concerns and
to maximize the likelihood of achieving a 24-h ratio of area under
the curve to MIC (AUC/MIC) of greater than 400, expert guide-
lines now recommend more-intensive vancomycin dosing and
maintenance of troughs between 15 mg/liter and 20 mg/liter for
serious MRSA infections (7–9).
The recommendation to maintain troughs between 15 and 20
mg/liter for seriousMRSA infections has beenwidely integrated into
clinical practice. Despite its adoption, there are (10) limited data to
suggest that maintenance of vancomycin trough values between 15
and 20 mg/liter improves outcomes (8, 10). Furthermore, the wide-
spreaduseof themore-intensive vancomycindosing schedules advo-
cated by recent guidelines has been associatedwith increasing reports
of vancomycin-induced nephrotoxicity. Nephrotoxicity is a long-
standing, yet highly debated, adverse effect associatedwith vancomy-
cin administration (1). Initial reports of vancomycin-induced neph-
rotoxicity were largely attributed to impurities in the original
formulation. Followingmodern fermentationmethods andpurifica-
tion, nephrotoxicity was considered to be infrequent (5 to 7%) and
reversible (1, 11, 12). With increasing reports of vancomycin-in-
duced nephrotoxicity in the “15-to 20-mg/liter” vancomycin trough
era, there is a renewed interest in evaluating the relationship between
vancomycin trough concentrations and incidence of nephrotoxicity
(13–16). Although there are a few recent review articles on this topic,
no group has attempted to quantify systematically the risk associated
with increasedvancomycin trough levels (17–19).Thepurposeof this
systematic literature review and meta-analysis is to determine the
nephrotoxicity potential of maintaining higher troughs (15 mg/
liter) in clinical practice.
MATERIALS AND METHODS
Search strategy and selection criteria. Studies were retrieved from the
PubMed, Embase, Cochrane Controlled Trial Registry, and Medline da-
tabases from January 1995 to April 2012. Search terms included “vanco-
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mycin” in combinationwith “nephrotoxicity” or “renal toxicity” or “renal
injury.” References were also identified from the bibliographies of studies
retrieved from the literature search. Studies written in languages other
than English and those presented solely as abstracts at scientific confer-
ences were not considered in this analysis.
Study selection.The abstracts of all studieswere reviewed.A studywas
considered eligible for inclusion if the observed nephrotoxicity rates could
be extracted and stratified by vancomycin troughs (15 versus15 mg/
liter). Studies in which vancomycin was administered by continuous in-
fusion were excluded to ensure uniformity in vancomycin administration
across studies. When data pertinent to our review were missing, authors
were contacted (whenever possible) to provide further details.
Data extraction, outcomes, and data analysis. Data extracted from
the identified studies included clinical setting, number of patients studied,
inclusion and exclusion criteria, definitions of nephrotoxicity, and con-
comitant risk factors for nephrotoxicity (age, residence in intensive care
unit [ICU], severity of illness, and receipt of concomitant nephrotoxins as
defined in each study). Additional information extracted included vanco-
mycin treatment duration, vancomycin trough levels, and patient out-
comes, if available.
Analyzed outcomes. The primary outcome was incidence of vanco-
mycin nephrotoxicity among patients with high vancomycin troughs
(15 mg/liter) relative to those with low vancomycin troughs (15 mg/
liter). Since the definition of nephrotoxicity varied slightly across the stud-
ies, the nephrotoxicity definition employed in the reviewed study was
used in the primary outcome analysis. In addition to the primary analysis,
several restricted analyses were performed. These restricted analyses in-
cluded studies (i) that were limited to adults (18 years of age), (ii) that
evaluated the relationship between initial trough values (high versus low)
and nephrotoxicity, (iii) that examined the risk of nephrotoxicity across
more demarcated trough strata (10, 10 to 15, 15 to 20, and 20 mg/
liter), (iv) that assessed the effect of duration of therapy on incidence of
nephrotoxicity, and (v) that only had authors with no declared conflicts of
interest with pharmaceutical companies. Secondary outcomes examined
included mortality, hospital length of stay, reversibility of the nephrotox-
icity, and need for renal replacement therapy following a nephrotoxic
event.
Data analysis and statistical methods. Data analysis was performed
using Review Manager (RevMan), version 5.1 (The Cochrane Collabora-
tion, 2011, TheNordic CochraneCentre, Copenhagen). Odds ratios (OR)
and 95% confidence intervals (CI) for dichotomous variables were calcu-
lated.Meta-analysis was performed using fixed-effects models, unless sig-
nificant heterogeneity was observed, inwhich case random-effectsmodels
were used. Heterogeneity was assessed using the chi-square test with the
extent of inconsistency assessed using I2 statistics. A P value of 0.05 was
regarded as significant.
RESULTS
Our literature search identified 240 studies. Of the 240 studies, 38
studies were reviewed and 15 were included in the meta-analysis
(8, 13–16, 20–52). Twenty-three studies were excluded for the
following reasons: nephrotoxicity data were not presented by van-
comycin trough strata (15 versus15 mg/liter; 20 studies) (16,
20, 24, 25, 27–29, 33–35, 37, 41, 42, 44–47, 49, 52); nephrotoxicity
data were stratified by alternative vancomycin trough strata (10
versus10 mg/liter; 1 study) (26); the study was a case report (1
study) (40); and vancomycin was administered as a continuous
infusion (2 studies) (14, 48).
The remaining 15 studies were included in the meta-analysis
(Table 1) (8, 13, 15, 21–23, 30–32, 36, 38, 39, 43, 50, 51). Of these,
14 studies were conducted with adults and 1 involved children
(38) (Table 1). The average trough value over the duration of
therapy was examined in 6 studies (13, 30, 38, 39, 43, 50), and the
initial trough value was considered in 8 studies (8, 15, 21–23, 32,
36, 51). Although timing differed between studies, most initial
trough levels were obtained at the time or shortly after steady state
was achieved (i.e., after the 3rd dose) but not greater than 4 days
into therapy (Table 2). In patients with multiple levels during this
initial period, the highest trough (22, 36) or the average trough
(21) was used to define the trough exposure in the parent analysis.
Four studies categorized vancomycin into more precisely defined
trough strata (8, 22, 36, 50), while four studies provided data for
nephrotoxicity as a function of duration of vancomycin therapy
(13, 15, 39, 43).
Nephrotoxicity. The incidence of nephrotoxicity varied be-
tween studies from 5% to 43%. On average, nephrotoxicity oc-
curred between 4.3 and 17 days after initiation of vancomycin
therapy (13, 21, 22, 30, 32, 36, 38, 39, 43, 51). The definition of
nephrotoxicity was identical (increase in serum creatinine [SCR]
of 0.5 mg/dl, equivalent to 44.2 mol/liter or 50% from baseline
on 2 consecutive measurements) in all but three studies (Table 1).
Of the three dissimilar studies, one used the Acute Kidney Injury
Network classification of nephrotoxicity (23), one employed the
Risk-Injury-Failure-Loss-End-stage-renal disease (RIFLE) classi-
fication of nephrotoxicity (39), and one used a nonstandardized
definition of nephrotoxicity (increase in SCR by 20% frombaseline
or110 mol/liter or a decrease of creatinine clearance by0.7
ml/s, equivalent to 42 ml/min) (31).
In the primary analysis, higher troughs (15 mg/liter) were
associated with increased nephrotoxicity (OR, 2.67; 95% CI, 1.95
to 3.65; P 0.01) relative to low troughs (15 mg/liter) (Fig. 1).
The results did not change considerably when the analysis was
restricted to adult patients (OR, 2.54; 95% CI, 1.84 to 3.50; P 
0.01) (38). The odds of nephrotoxicity among patients with
troughs of 15 mg/liter remained increased (OR, 3.12; 95% CI,
1.81 to 5.37; P 0.01) when the data were limited to studies that
examined initial vancomycin trough values (8, 15, 21–23, 32, 36,
51) (Fig. 2). In addition, troughs of15mg/liter remained signif-
icantly associated with nephrotoxicity when articles (8, 13, 21, 22,
30, 36, 43) in which authors declared potential conflicts of inter-
ests with pharmaceutical companies were excluded (OR, 2.84;
95% CI, 1.65 to 4.87; P 0.01).
Only four studies provided nephrotoxicity rates as a function
of incremental vancomycin trough values that confirmed the
presence of an exposure-toxicity gradient (8, 22, 36, 50) (Fig. 3).
All three found the highest rates of nephrotoxicity among patients
with troughs of20 mg/liter and the lowest rates among patients
with troughs of10 mg/liter. Two of the four studies found sim-
ilar risks of nephrotoxicity between patients with troughs of 15 to
20 mg/liter and 10 to 15 mg/liter. In studies in which the duration
of vancomycin therapy was analyzed, an incremental increase in
nephrotoxicity (6% to 45%)was notedwith longer durations (7 to
14 days) of therapy relative to shorter durations (Table 2).
Three studies stratified baseline clinical characteristics by high
(15 mg/liter) and low (15 mg/liter) vancomycin troughs (13,
30, 38). A number of nephrotoxicity risk factors (e.g., increased
severity of illness, receipt of concomitant nephrotoxins, and
source of infection) were more pronounced in patients with high
troughs than in those with low troughs. Patients in the ICU (OR,
2.57; 95% CI, 1.44 to 4.58; P 0.01) were more likely to develop
vancomycin-induced nephrotoxicity than were patients in non-
ICU wards (Fig. 4). Conversely, patients receiving concomitant
nephrotoxins (OR, 3.30; 95% CI, 1.30 to 8.39; P  0.01) were
more likely to develop vancomycin-induced nephrotoxicity than
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were patients who did not receive nephrotoxins (Fig. 5). These
findings, however, were not uniform across studies. To adjust for
potential confounders, several groups performed multivariate
analyses (15, 21, 22, 36, 38, 39, 43). In five of the seven studies, high
vancomycin troughs (15 mg/liter) remained an independent
predictor of nephrotoxicity (Table 2).
Renal and clinical outcomes. In studies that reported on the
clinical course of patients with vancomycin-induced nephrotox-
icity, SCR levels returned to baseline or below predefined toxicity
thresholds despite continuation of vancomycin in a substantial
proportion of cases (35% to 46%) (36, 38, 43). In situations where
vancomycin was discontinued, most episodes (44% to 75%) were
reported to resolve within a week or less (15, 38, 39, 43, 51). In
contrast, one study reported more-prolonged renal injury with
SCR levels remaining toxic (50% of baseline value) for7 days
in over 50% of episodes (36). Short-term dialysis was required in
a minority of patients (3%; 6 of 192 patients), and no patient was
reported to require long-term dialysis (26, 36, 38, 43, 51). Neph-
rotoxicity was associatedwith increased overallmortality (39) and
prolonged hospital (8, 39) and ICU (22) lengths of stay.
Heterogeneity and publication bias. There was significant
heterogeneity between the studies with different patient popula-
tions studied, nephrotoxicity definitions used, durations of van-
comycin treatment required for inclusion, and measurements of
trough level used in the analyses. As such, the random-effects
model was required in all analyses.
DISCUSSION
The collective findings of this systematic review strongly suggest
that adherence to the vancomycin trough recommendations in
recent expert guidelines may result in an elevated risk of vanco-
mycin-induced nephrotoxicity. Overall, maintaining troughs in
excess of 15mg/liter was found to substantially increase the risk of
a nephrotoxic event (Fig. 2). The relationship between troughs of
15mg/liter and nephrotoxicity persisted when the analyses were
restricted to studies that examined initial trough values. Interest-
ingly, data from 4 of the 15 studies suggest that a trough-toxicity
gradient exists, with the greatest risk observed among individuals
with troughs of20 mg/liter (Fig. 3). The probability of a neph-
rotoxic event was also found to increase as a function of treatment
duration, with most episodes occurring after 7 days of therapy.
Lastly, data, albeit limited, may be applicable to children.
While the association between vancomycin trough and neph-
rotoxicitywas largely uniformacross studies, the incidence of van-
comycin-induced nephrotoxicity was highly variable. Nephrotox-
icity rates ranged between 5% and 43% and were highly
dependent on the population evaluated. Not surprisingly, the
highest nephrotoxicity rates were observed in studies that in-
cluded a high percentage of critically ill patients that resided in the
ICUand received concomitant nephrotoxins. It is well known that
these populations have an elevated baseline risk of nephrotoxicity,
independent of vancomycin exposure. While this suggests that
vancomycin may not be responsible for the observed toxicity
rates, a high vancomycin trough,15 mg/liter, was still indepen-
dently associated with a higher odds of nephrotoxicity in most
studies that accounted for these variables in a multivariate analy-
sis. Together, these findings imply that high vancomycin troughs
augment the risk of nephrotoxicity, especially in the presence of
conditions known to be independently associated with nephro-
toxicity. Conversely, these medical factors likely affect the vanco-M
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mycin trough concentration threshold at which the risk of neph-
rotoxicity is likely to increase.
The multifactorial nature of vancomycin-induced nephrotox-
icity is best highlighted by the findings of two recent randomized
clinical trials (50, 53). In the ceftaroline fosamil versus vancomy-
cin/aztreonam for complicated skin and skin structure infections
(cSSSI) clinical trial, the incidence of nephrotoxicity in the vanco-
mycin armwas 1.3%, only 0.9%greater than in the ceftaroline arm
(53). Of note, patients in this study rarely resided in the ICU,
generally had troughs of10mg/liter, and typically received ther-
apy for10 days. In comparison, the incidence of nephrotoxicity
was 9.6% greater with vancomycin than with linezolid in the re-
cent phase IV vancomycin versus linezolid for nosocomial MRSA
pneumonia clinical trial. In this study, patients were generally in
poorer health (the mean Acute Physiology and Chronic Health
Evaluation [APACHE II] score was 17.6), with 64% of patients
requiring ventilation (50).
While the incidence of nephrotoxicity is concerning, it appears
to be largely reversible in the majority of cases following vanco-
mycin discontinuation (36, 38, 43, 51). Short-term dialysis was
required in only approximately 3% of cases, and no patient
needed long-term dialysis. All patients who required dialysis also
received concomitant nephrotoxins (43). This finding supports
the notion that certain clinical factors augment the severity of
vancomycin-induced renal impairment. Although vancomycin-
induced nephrotoxicity was generally reversible, it should be
noted that the nephrotoxic events were associated with increased
lengths of stay and poorer outcomes (39, 54).
Several issues should be considered when interpreting these
results. First, it is a challenge to completely establish that expo-
sure-nephrotoxicity relationships exist for drugs that are renally
eliminated. Since vancomycin is eliminated predominantly by
glomerular filtration, a decrease in renal function from any cause
will increase vancomycin serum concentrations (13, 15). Cogni-
zant of this, we performed an analysis limited to studies that ex-
amined only initial troughs. The odds of nephrotoxicity remained
increased, at 3.12 (95% CI, 1.81 to 5.37; P  0.01) for patients
attaining initial trough levels of15mg/liter (8, 13, 21, 22, 30, 36,
43). The presence of a vancomycin trough-nephrotoxicity rela-
tionship is further substantiated when one considers that most
FIG 1 Forest plot (using Mantel-Haenszel [M-H] analysis) of events denoting nephrotoxicity associated with vancomycin, comparing rates for trough levels of
15 mg/dl and15 mg/dl. Squares indicate point estimates, and the size of the square indicates the weight of each study.
FIG 2 Forest plot (using Mantel-Haenszel [M-H] analysis) of events denoting nephrotoxicity associated with vancomycin, comparing rates for initial trough
levels of15 mg/dl and15 mg/dl. Squares indicate point estimates, and the size of the square indicates the weight of each study. All initial trough levels were
obtained at the time or shortly after steady state was achieved (i.e., after the 3rd dose) and not greater than 4 days into therapy (see Table 2 for more details).
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nephrotoxic events occurred after 7 days of therapy (13, 15, 39,
43). This exposure-toxicity relationship is biologically plausible
and supported by recent animal and human data that suggest van-
comycin acts as an oxidative stressor in proximal renal tubular
cells (55–61).
Second, the results of the analysis that categorized vancomycin
into more precisely defined trough strata (10, 10 to 15, 15 to 20,
and20 mg/liter) suggest that vancomycin-induced nephrotox-
icity is similar among patients with troughs between 10 and 20
mg/liter and greatest among patients with troughs in excess of 20
mg/liter. Due to the small demarcation in trough values between
10 to 15 and 15 to 20 mg/liter, there was a high potential for
vancomycin stratum misclassification error, especially as these
data are derived from retrospective cohort studies.While it is pos-
sible that vancomycin trough values of20 mg/liter may be driv-
ing the nephrotoxicity in the15-mg/liter strata, caution should
be exercised before drawing definitive conclusions from these data
(8, 22, 36, 50). Until more data are available to adequately define
the vancomycin exposure-toxicity curve, clinicians should rely on
the collective results of the 15 studies included in this meta-anal-
ysis, which suggest that an augmented risk of toxicity occurs in
individuals with troughs of15mg/liter (8, 13–15, 21–23, 30–32,
36, 38, 39, 43, 48, 50, 51).
Third, it was difficult to fully quantify the role of concomitant
nephrotoxins in the observed results. It is quite possible that the
role of concomitant nephrotoxinsmay have been underestimated.
The number of concomitant nephrotoxins listed in each study
varied, and some studies provided only examples of nephrotoxic
agents rather than an exhaustive list (8, 36). No data on the rela-
tionship between the number of concurrent nephrotoxins and
observed nephrotoxicity results were provided. Although defini-
tions of concomitant use were similar across all studies except one
(31), the effects of duration and timing of concomitant nephro-
toxins on vancomycin-associated nephrotoxicity were not quan-
tifiable.
Fourth, we could not exclude the presence of publication bias;
positive studies aremore likely to be published than negative ones.
In addition, a targeted analysis taking into account all confound-
ers was not possible; this limited the ability of thismeta-analysis to
definitively establish the presence of a causal relationship. Asmost
studies included were retrospective observational cohorts, treat-
FIG 3 Incidence of vancomycin nephrotoxicity with rising trough levels (8, 22, 36, 50).
FIG 4 Forest plot (usingMantel-Haenszel [M-H] analysis) of events denoting nephrotoxicity associated with vancomycin, comparing rates for patients residing
in ICU or the ward at the time of diagnosis. Squares indicate point estimates, and the size of the square indicates the weight of each study.
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ment selection bias and management decisions with respect to
dosage adjustments could not be analyzed.
In conclusion, the findings from this systematic literature re-
view strongly suggest that a relationship exists between the vanco-
mycin trough value and nephrotoxicity. Patients with vancomy-
cin troughs in excess of 15 mg/liter were found to have a greater
risk of nephrotoxicity than did patients with troughs of15 mg/
liter. The incidence of toxicity increased as a function of therapy
duration, with the highest rates observed among critically ill indi-
viduals that resided in the ICU and received concomitant neph-
rotoxins. These observed results have important clinical implica-
tions and suggest that initial trough concentrations can serve as a
prognostic indicator for nephrotoxicity and to identify patients
that require careful monitoring. Based on collective findings, cli-
nicians should intently monitor the renal function of patients re-
ceiving vancomycin, especially those patients being maintained at
a trough value in excess of 15 mg/liter. Unfortunately, data on
practical management decisions with respect to how and when to
adjust the dose or cease vancomycin therapy remain lacking, and
these issues require urgent study.
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